Infixion Bioscience is Awarded Third NIH SBIR Phase 1 Grant to Develop Therapeutics for Neurofibromatosis (NF1)

SAN DIEGO, Sept. 20, 2022 /PRNewswire/ — Infixion Bioscience, a pre-clinical drug discovery company focused on developing gene-targeted therapeutics for the rare genetic disorder Neurofibromatosis Type 1 (NF1), announced today the awarding of its third NIH SBIR Phase 1 grant from the…

Click here to view original post